ClinicalTrials.gg
WithdrawnNCT04632160Updated Aug 2, 2021

Extended IASD Investigation: REDUCE LAP-HF IV

An interventional study of IASD System II in Heart Failure With Preserved Ejection Fraction and Heart Failure With Mid Range Ejection Fraction, sponsored by Corvia Medical. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-08-02.

Sponsored by Corvia Medical · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Withdrawn pending formal analysis of REDUCE LAP-HF II Pivotal Study results

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

Multicenter, Prospective, Open Label, Single Arm, Clinical Trial.

The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients with an left ventricular ejection fraction (LVEF) ≥ 40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT); and to compare the safety and efficacy results to those from the treatment arm of the REDUCE LAP-HF Randomized Trial II (Corvia protocol 1601).

Read the detailed description

Participants are screened against non-invasive eligibility criteria and scheduled for a hemodynamic evaluation. Following right heart catheterization at rest and during supine bicycle exercise, patients will undergo a brief intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE) exam for septal suitability.

Eligible patients continue with, fluoroscopically and echo guided transseptal puncture and IASD System II implant procedure. If a previously unknown protocol exclusion is discovered during the index procedure, and device is not implanted, participant is followed for 30 days, and then exits the study.

Participants return for follow-up exams 30 days after the implant procedure and annually for 5 years after the implant procedure. In-person visits will take place for the first 2 years. Telephone follow-up and medical chart review will be conducted for years 3-5.

02

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mid Range Ejection Fraction

Browse trials for

03

In context

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Lead sponsor

Corvia Medical is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  • Chronic symptomatic heart failure with preserved or mid-range (HFpEF or HFrEF)
  • Participant is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams

Select Exclusion Criteria:

  • Myocardial infarction and/or percutaneous cardiac intervention within past 3 months; Coronary artery bypass surgery in past 3 months, or current indication for coronary revascularization; AVR (surgical AVR or TAVR) within the past 12 months
  • Advanced heart failure
  • History of stroke, (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 6 months
  • Significant heart valve disease
  • Chronic pulmonary disease
  • Women of
  • Severe obstructive sleep apnea not treated with CPAP or other measures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment

    Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.

    Device: IASD System II

Interventions

  • DeviceIASD System II

    The implant is placed across the interatrial septum using a percutaneous transcatheter approach.

    Also known as: Interatrial Shunt Device

06

What researchers measure

Primary outcomes

  1. Incidence of and time-to-cardiovascular mortality or first non-fatal, ischemic stroke through 12 months

    Time frame: 12 Month

  2. Total rate (first plus recurrent) per patient year of heart failure (HF) admissions or healthcare facility visits for IV diuresis for HF up to 24 months, analyzed when the last subject completes 12 month follow-up, and time-to-first HF event

    Time frame: Up to 24 Months

  3. Change in baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) total summary score at 12 months

    Time frame: 12 Month

Secondary outcomes

  1. Cardiovascular mortality through 12 months

    Time frame: 12 Months

  2. Non-fatal, ischemic stroke through 12 months

    Time frame: 12 Months

  3. New onset or worsening of kidney dysfunction (defined as eGFR decrease of > 20 ml/min/1.73 m2) through 12 months

    Time frame: 12 Months

  4. Incidence of Major Cardiac Events i. Cardiac death ii. Myocardial infarction iii. Cardiac tamponade iv. Emergency cardiac surgery.

    Time frame: 12 Months

  5. Thrombo-embolic complications (TIA, systemic embolization) through 12 months

    Time frame: 12 Months

  6. ≥30% increase in right ventricular size/decrease in TAPSE through 12 months

    Time frame: 12 Months

  7. Newly acquired persistent or permanent AF or atrial flutter through 12 months

    Time frame: 12 Months

  8. Total rate per patient year of heart failure admissions or healthcare facility visits for IV diuresis or visits with intensification of oral diuresis for HF through 24 months, analyzed when the last subject completes 12 months follow-up

    Time frame: Up to 24 months

  9. Change in New York Heart Association (NYHA) functional Class between baseline and 12 months

    Time frame: 12 Months

  10. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score between baseline and 12 months, categorized as ≤0, >0 - 5, >5 - 10, >10 - 15, >15 - 20, >20 - 25, >25.

    Time frame: 12 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2021; primary completion for Jan 2022, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 17, 2020
StartEst.
Dec 1, 2021
Primary completionEst.
Jan 1, 2022
CompletionEst.
Jan 1, 2027
Last update
Aug 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04632160
Lead sponsor
Corvia Medical
Responsible party
Sponsor
First posted
Nov 17, 2020
Start date
Dec 1, 2021 (estimated)
Primary completion
Jan 1, 2022 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Aug 2, 2021

Study contacts

Sanijv Shah, MD
principal investigator · Northwestern Memorial Hospital
Marty Leon, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion